中国麻风皮肤病杂志 ›› 2018, Vol. 34 ›› Issue (9): 573-576.

• 综述 • 上一篇    

皮肤外用制剂生物利用度及生物等效性研究进展

吴黎莉 陈沄   

  1. 中国医学科学院北京协和医学院皮肤病研究所,南京,210042
  • 出版日期:2018-09-15 发布日期:2018-12-11
  • 通讯作者: 陈沄,E-mail: sxmcysissi@163.com

Upate of bioavailability and bioequivalence of topical dermatological drugs

WU Lili, CHEN Yun   

  1. Department of pharmacology, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing 210042, China
  • Online:2018-09-15 Published:2018-12-11
  • Contact: CHEN Yun, E-mail: sxmcysissi@163.com

摘要: 皮肤外用制剂要求在皮肤局部发挥药效,口服给药药物的生物利用度研究方法对于皮肤外用制剂并不适用。目前血管收缩测定法已被FDA认可,但该法只适用于糖皮质激素类药物,其他外用制剂仍需通过临床对比试验来评价其生物等效性。FDA仍在努力寻找其他的研究方法,如胶带粘贴法、皮肤微透析法、开流微量灌注及体外研究方法。本文对以上方法的研究进展进行综述。

关键词: 外用制剂, 生物利用度, 生物等效性

Abstract: Topical dermatologic drugs take effect at the target skin and the bioequivalence study methods for orally administrated drugs may not be applicable to topical dermatologic drug. Currently, vasoconstrictor assay (VCA)has been approved by FDA, but which is only applied?to glucocorticoid drugs. The bioequivalence of other topical preparations is evaluated through clinical end-point trials. FDA is still trying to explore other methods for bioavailability, such as tape stripping, dermal microdialysis, open flow perfusion and in vitro studies. The update of above methods is reviewed in this article.

Key words: topical dermatological drug products, bioavailability, bioequivalence

中图分类号: